Inspire Drops Epinastine After Phase III Fizzle
This article was originally published in The Pink Sheet Daily
Executive Summary
Non-steroidal nasal spray for allergic rhinitis is the firm’s second casualty this year.
You may also be interested in...
Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate
Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.
Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate
Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.
Inspiring Results For Phase III Disease-Modifying Cystic Fibrosis Drug
Inspire Pharmaceuticals' denufosol showed improvement in FEV1 versus placebo over 24 weeks.